von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD

Leebeek, 2016, Von Willebrand’s disease, N Engl J Med, 375, 2067, 10.1056/NEJMra1601561 de Wee, 2012, Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease, Thromb Haemost, 108, 683, 10.1160/TH12-04-0244 de Wee, 2010, Health-related quality of life among adult patients with moderate and severe von Willebrand disease, J Thromb Haemost, 8, 1492, 10.1111/j.1538-7836.2010.03864.x Lavin, 2018, Significant gynecological bleeding in women with low von Willebrand factor levels, Blood Adv, 2, 1784, 10.1182/bloodadvances.2018017418 Sharma, 2017, Advances in the diagnosis and treatment of von Willebrand disease, Blood, 130, 2386, 10.1182/blood-2017-05-782029 Leebeek, 2019, How I manage severe von Willebrand disease, Br J Haematol, 187, 418, 10.1111/bjh.16186 Atiq, 2018, Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease, Br J Haematol, 182, 93, 10.1111/bjh.15277 Atiq, 2019, BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease, Am J Hematol, 94, E201, 10.1002/ajh.25499 Sanders, 2015, CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease, J Thromb Haemost, 13, 956, 10.1111/jth.12927 Federici, 2014, The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease, Blood, 123, 4037, 10.1182/blood-2014-02-557264 Sadler, 2000, Impact, diagnosis and treatment of von Willebrand disease, Thromb Haemost, 84, 160, 10.1055/s-0037-1613992 Kawecki, 2017, von Willebrand factor and inflammation, J Thromb Haemost, 15, 1285, 10.1111/jth.13696 Prentice, 1972, Rise of factor VIII after exercise and adrenaline infusion, measured by immunological and biological techniques, Thromb Res, 1, 493, 10.1016/0049-3848(72)90056-4 van Loon, 2014, Performance related factors are the main determinants of the von Willebrand factor response to exhaustive physical exercise, PLoS One, 9, e91687, 10.1371/journal.pone.0091687 Heijdra, 2017, Current and emerging options for the management of inherited von Willebrand disease, Drugs, 77, 1531, 10.1007/s40265-017-0793-2 Candy, 2018, A decreased and less sustained desmopressin response in hemophilia A carriers contributes to bleeding, Blood Adv, 2, 2629, 10.1182/bloodadvances.2018023713 Atiq, 2019, Sports participation and physical activity in patients with von Willebrand disease, Haemophilia, 25, 101, 10.1111/hae.13629 Federici, 2008, The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007), Haemophilia, 14, 5, 10.1111/j.1365-2516.2007.01610.x Bodó, 2015, Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH, J Thromb Haemost, 13, 1345, 10.1111/jth.12964 Tosetto, 2008, Bleeding scores in inherited bleeding disorders: clinical or research tools?, Haemophilia, 14, 415, 10.1111/j.1365-2516.2007.01648.x Sanders, 2015, Von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease, Blood, 125, 3006, 10.1182/blood-2014-09-603241 Castaman, 2008, Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD, Blood, 111, 3531, 10.1182/blood-2007-08-109231 Tosetto, 2006, A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD), J Thromb Haemost, 4, 766, 10.1111/j.1538-7836.2006.01847.x Flood, 2018, Von Willebrand disease in the United States: perspective from the Zimmerman program, Ann Blood, 3, 3, 10.21037/aob.2017.12.05 Lavin, 2017, Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels, Blood, 130, 2344, 10.1182/blood-2017-05-786699 Flood, 2016, Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States, Blood, 127, 2481, 10.1182/blood-2015-10-673681 Mannucci, 1981, Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand’s disease: effects on replacement therapy, Blood, 57, 25, 10.1182/blood.V57.1.25.25 James, 2013, Alloantibodies in von Willebrand disease, Blood, 122, 636, 10.1182/blood-2012-10-462085 Mannucci, 2017, Laboratory monitoring of replacement therapy for major surgery in von Willebrand disease, Haemophilia, 23, 182, 10.1111/hae.13165 van Galen, 2015, Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study, Haemophilia, 21, e185, 10.1111/hae.12670 van Galen, 2017, Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study, Haematologica, 102, 1486, 10.3324/haematol.2017.168617 Rodeghiero, 1989, Consistency of responses to repeated DDAVP infusions in patients with von Willebrand’s disease and hemophilia A, Blood, 74, 1997, 10.1182/blood.V74.6.1997.1997 Carroll, 2006, Measurement Error in Nonlinear Models: A Modern Perspective, 10.1201/9781420010138 Boender, 2018, Clinically relevant differences between assays for von Willebrand factor activity, J Thromb Haemost, 16, 2413, 10.1111/jth.14319